131 related articles for article (PubMed ID: 38666379)
1. Antiarrhythmic and Anti-Inflammatory Effects of Sacubitril/Valsartan on Post-Myocardial Infarction Scar.
Martínez-Falguera D; Aranyó J; Teis A; Ferrer-Curriu G; Monguió-Tortajada M; Fadeuilhe E; Rodríguez-Leor O; Díaz-Güemes I; Roura S; Villuendas R; Sarrias A; Bazan V; Delgado V; Bayes-Genis A; Bisbal F; Gálvez-Montón C
Circ Arrhythm Electrophysiol; 2024 May; 17(5):e012517. PubMed ID: 38666379
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
[TBL] [Abstract][Full Text] [Related]
3. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
[TBL] [Abstract][Full Text] [Related]
4. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
7. LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Chang PC; Lin SF; Chu Y; Wo HT; Lee HL; Huang YC; Wen MS; Chou CC
Cardiovasc Ther; 2019; 2019():6032631. PubMed ID: 31772612
[TBL] [Abstract][Full Text] [Related]
8. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model.
Zhang H; Zhong H; Everett TH; Wilson E; Chang R; Zeng D; Belardinelli L; Olgin JE
Heart Rhythm; 2014 Jan; 11(1):101-9. PubMed ID: 24120874
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
11. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional cardiac fibre disorganization as a novel parameter for ventricular arrhythmia stratification after myocardial infarction.
León DG; López-Yunta M; Alfonso-Almazán JM; Marina-Breysse M; Quintanilla JG; Sánchez-González J; Galán-Arriola C; Castro-Núñez F; González-Ferrer JJ; Ibáñez B; Pérez-Villacastín J; Pérez-Castellano N; Fuster V; Jalife J; Vázquez M; Aguado-Sierra J; Filgueiras-Rama D
Europace; 2019 May; 21(5):822-832. PubMed ID: 30649290
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation.
Li LY; Lou Q; Liu GZ; Lv JC; Yun FX; Li TK; Yang W; Zhao HY; Zhang L; Bai N; Zhan CC; Yu J; Zang YX; Li WM
Eur J Pharmacol; 2020 Aug; 881():173120. PubMed ID: 32325147
[TBL] [Abstract][Full Text] [Related]
14. Electrical homogenization of ventricular scar by application of collagenase: a novel strategy for arrhythmia therapy.
Yagishita D; Ajijola OA; Vaseghi M; Nsair A; Zhou W; Yamakawa K; Tung R; Mahajan A; Shivkumar K
Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):776-83. PubMed ID: 23873142
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
16. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
[TBL] [Abstract][Full Text] [Related]
17. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
